Simple Summary Malignant pleural mesothelioma (MPM) is a rare cancer with an
aggressive disease course. For patients who are medically inoperable or surgically …

Purpose Multiple phase 2 trials of neoadjuvant treatment intensification in locally advanced
rectal cancer have reported promising efficacy signals, but these have not translated into …

Purpose: The best phase II design and endpoint for growth inhibitory agents is controversial.
We simulated phase II trials by resampling patients from a positive (sorafenib vs. placebo; …

The rate of failure in phase III oncology trials is surprisingly high, partly owing to inadequate
phase II studies. Recently, the use of randomized designs in phase II is being increasingly …

Cancer pharmacology encompasses the full spectrum of therapeutic issues. In the earliest
stages of new drug discovery, translational research has led to more sophisticated …

In the era of precision medicine, there is a desire to harness our improved understanding of
genomic and molecular underpinnings of gliomas to develop therapies that can be tailored …

Background The article aims to compare the efficiency of minimax, optimal and admissible
criteria in Simon's and Fleming's two-stage design. Methods Three parameter settings (p 1-p …

Lay Summary Despite longer survival with immune checkpoint inhibitors targeting
programmed cell death protein 1 (PD‐1)/programmed cell death–ligand 1 (PD‐L1) …

Purpose The optimal end point for randomized phase II trials of anticancer therapies
remains controversial. We simulated phase II trials by resampling patients from N9741, a …

Tumor vaccination holds great promise for the treatment of cancer and research concerning
tumor vaccination in dogs is of great interest for veterinary as well as human medicine …